All In MedTech

Device Trial Radar · NCT02989948

Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA

Safety and Effectiveness of Physician-Modified Fenestrated and Branched Aortic Endografting for the Treatment of Thoracoabdominal Aortic Aneurysms (TAAA)

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 22, 2020

Primary completion

Dec 31, 2027

Study completion Dec 31, 2031

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 12, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 50 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary clinical objective of this study is to evaluate the safety and effectiveness of a physician-modified, fenestrated and branched aortic endoprosthesis for the treatment of thoracoabdominal aortic aneurysms (TAAAs). The goal of the primary analysis is to demonstrate both the safety and effectiveness of using a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft as compared to previously published results of open surgical replacement of the aneurysmal aorta.

Conditions

  • Aortic Aneurysm, Thoracoabdominal

Interventions

  • Physician-modified aortic endograftDevice

    Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 30 day survivalTime frame: 30 Days
  2. Major Adverse Events (MAE) at 30 days following surgeryTime frame: 30 Days
  3. Treatment success at 12 months following surgeryTime frame: 12 Months

1 more outcomes with a free account

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Yale New Haven Hospital

    New Haven, Connecticut · Recruiting

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.